Related Experiment Video
Updated: Jul 15, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Vascular calcification in chronic kidney failure: role of vitamin D receptor
1Abbott Laboratories, 100 Abbott Park Rd, Abbott Park, IL 60064, USA. ruth.r.wuwong@abbott.com
Insights
Vitamin D receptor activator (VDRA) therapy offers survival benefits for chronic kidney disease (CKD) patients, despite concerns about vascular calcification. Different VDRAs may differentially impact CKD-related cardiovascular risks.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Endocrinology
Background:
- Chronic kidney disease (CKD) patients face higher cardiovascular disease and mortality risks, linked to atherosclerosis and vascular calcification.
- Vascular calcification is a regulated process involving an imbalance of inducing and inhibitory factors, with specific factors remaining unidentified.
- The vitamin D receptor (VDR) is a nuclear receptor, and its activators (VDRAs) like paricalcitol and calcitriol treat secondary hyperparathyroidism in CKD.
Purpose of the Study:
- To investigate the role of VDRAs in vascular calcification within CKD patients.
- To reconcile the observed survival benefits of VDRA therapy with potential pro-calcification effects.
- To explore differential effects of VDRAs on endocrine versus paracrine/autocrine VDR pathways.
Main Methods:
- Literature review of existing studies on VDRA therapy and vascular calcification in CKD.
- Analysis of clinical observations regarding VDRA therapy and patient survival, independent of mineral levels.
- Examination of potential mechanisms by which VDRAs might influence vascular health.
Main Results:
- Clinical data indicate a survival benefit order for VDRA therapy: paricalcitol > calcitriol > no VDRA.
- This survival benefit exists independently of serum parathyroid hormone, phosphorus, and calcium levels.
- Current literature presents inconsistent findings on the impact of VDRAs on vascular calcification.
Conclusions:
- VDRA therapy demonstrates a survival advantage in CKD patients.
- The seemingly contradictory effects of VDRAs on survival and potential calcification warrant further investigation.
- Differential effects of various VDRAs on VDR signaling pathways may explain observed clinical outcomes.
Abstract:
Chronic kidney disease (CKD) patients encounter an increased risk of cardiovascular disease and mortality compared with healthy individuals, most likely due to the presence of severe atherosclerosis and accelerated vascular calcification. Vascular calcification is an active, regulated process resulting from an imbalance between losses in inhibitory factors and gains in inducing factors present in cells and the blood circulation. However, exactly which inhibitory and inducing factors are involved remains unknown. The vitamin D receptor (VDR) is a nuclear receptor present in over 30 different tissues. Several VDR activators (VDRAs), including paricalcitol and calcitriol, are currently available for the treatment of secondary hyperparathyroidism in patients with CKD. Recent clinical observations demonstrate that VDRA therapy provides survival benefits for CKD patients in the order of paricalcitol > calcitriol > no VDRA therapy, independent of serum parathyroid hormone, phosphorus and calcium levels. The survival benefit of VDRAs seems contradictory to the perception that VDRAs, due to their potential impact of increasing serum phosphorus and calcium, may cause calcification in vessels. A review of the current literature shows that inconsistent data exist regarding the role of VDRAs in vascular calcification. A possible explanation is that the VDR may be involved in regulating several different pathways as an endocrine, paracrine and/or autocrine factor, and different VDRAs may have differential effects on the endocrine versus the paracrine/autocrine aspect.
Related Concept Videos
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Skeleton and Calcium Homeostasis
Role of Skin in Vitamin D Synthesis
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin D3(cholecalciferol).
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction

